Effect of procalcitonin on the prognosis of patients with COPD.
C-reactive protein
chronic obstructive pulmonary disease
erythrocyte sedimentation rate
neutrophil percentage
procalcitonin
white blood cell count
Journal
Biomedical reports
ISSN: 2049-9434
Titre abrégé: Biomed Rep
Pays: England
ID NLM: 101613227
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
25
09
2019
accepted:
16
03
2020
entrez:
9
5
2020
pubmed:
10
5
2020
medline:
10
5
2020
Statut:
ppublish
Résumé
The aim of the present study was to investigate the effect of procalcitonin levels on the prognosis of chronic obstructive pulmonary disease (COPD), and its relationship with other indices of infection. Inpatients diagnosed with acute aggravation of COPD between January 2017 and June 2018 were enrolled in the present study. Troponin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, percentage of neutrophils (NE%), hospitalization days and hospitalization expenses were collected and followed up for half a year to observe the survival rate in patients with COPD and the risk of acute aggravation. There were 246 patients with procalcitonin (PCT) levels <0.1 ng/ml, among whom 55 were randomly selected and assigned to a PCT negative group; and another 55 patients with PCT levels ≥0.1 ng/ml were assigned to a PCT positive group. The serum CRP, ESR, WBC count, NE% and hospitalization expenses in the PCT positive group were significantly higher compared with the PCT negative group (P<0.05). There was a positive association between PCT levels and CRP, WBC, NE% and hospitalization expenses, but not between PCT and ESR. The number of AECOPD events occurring within half a year between the two groups was statistically significant (χ²=5.923; P<0.05), and there was no significant correlation between PCT and recurrence frequency. Together, the results of the present study suggest that the levels of PCT in patients with acute aggravation may reflect the severity of COPD and may be used as a reference value for prognostic risk assessment. Serum PCT levels may be used as an indicator to predict duration and cost of hospitalization.
Identifiants
pubmed: 32382415
doi: 10.3892/br.2020.1298
pii: BR-0-0-1298
pmc: PMC7201139
doi:
Types de publication
Journal Article
Langues
eng
Pagination
313-318Informations de copyright
Copyright: © Gong et al.
Références
Eur Respir J. 2008 Feb;31(2):416-69
pubmed: 18238951
Intensive Care Med. 2000 Mar;26 Suppl 2:S146-7
pubmed: 18470709
Clin Infect Dis. 2011 May;52 Suppl 4:S346-50
pubmed: 21460294
J Investig Med. 1997 Dec;45(9):552-60
pubmed: 9444882
Thorax. 2004 Oct;59(10):837-42
pubmed: 15454648
Pharmacotherapy. 2015 Jun;35(6):631-48
pubmed: 26032691
Nature. 1983 Oct 6-12;305(5934):534-6
pubmed: 6604878
Int J Chron Obstruct Pulmon Dis. 2017 Sep 08;12:2681-2686
pubmed: 28932111
Eur Rev Med Pharmacol Sci. 2013 May;17(10):1311-3
pubmed: 23740442
J Immunol. 2009 Jan 1;182(1):684-91
pubmed: 19109202
J Emerg Med. 1999 Nov-Dec;17(6):1019-25
pubmed: 10595891
Int J Chron Obstruct Pulmon Dis. 2017 Jan 31;12:467-475
pubmed: 28203070
Clin Pharmacol Ther. 2001 Mar;69(3):89-95
pubmed: 11240971
Am J Emerg Med. 2012 Sep;30(7):1248-54
pubmed: 22030193
J Clin Pathol. 2015 Sep;68(9):675-9
pubmed: 26124314
Swiss Med Wkly. 2001 Oct 20;131(41-42):595-602
pubmed: 11820070
Emerg Med Pract. ;19(10):1-24
pubmed: 28926214
Curr Opin Pulm Med. 2015 May;21(3):278-83
pubmed: 25719955
Chest. 2000 May;117(5 Suppl 2):380S-5S
pubmed: 10843981